In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

A randomised controlled trial of the effect of remote ischaemic pre-conditioning on coronary endothelial function in patients with angina (RIC-COR).

Session Poster session 1

Speaker David Corcoran

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : D Corcoran (Glasgow,GB), 1 Ric-Cor Investigators (Glasgow,GB), C Berry (Glasgow,GB)

D. Corcoran1 , 1 Ric-Cor Investigators2 , C. Berry1 , 1University of Glasgow, Institute of Cardiovascular and Medical Sciences - Glasgow - United Kingdom , 2Golden Jubilee National Hospital - Glasgow - United Kingdom ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 190

Background: Remote ischaemic pre-conditioning (RIC) has cardioprotective effects, however its mechanisms are incompletely understood.

Purpose: To determine whether RIC enhances coronary endothelial function in patients with coronary artery disease (CAD).

Methods: 75 patients with stable angina undergoing elective invasive management were prospectively enrolled, and randomised to RIC or sham prior to angiography. RIC comprised 4 cycles of intermittent arm sphygmomanometer cuff inflation (200mg for 5 minutes), followed by a rest interval (5 minutes). Sham involved cuff placement without inflation (5 minutes). Endothelial function testing by a blinded operator, involved a control intracoronary (IC) saline infusion, followed by IC acetylcholine (ACh) in incremental doses [10–6, 10–5, 10–4 M] via a 3F infusion catheter. Endothelial independent vasodilation was tested with IC glyceryl trinitrate bolus. Venous blood pre- and post-RIC/sham was obtained and analysed for circulating molecules regulating endothelial function (MPO, IL-6, tPA, vWF). Quantitative coronary angiography (QCA) was performed (blinded) to assess mean coronary luminal diameter change in the coronary segment distal to the infusion catheter or the main epicardial segment demonstrating the most marked diameter change. The primary outcome was the mean percentage change in coronary luminal diameter following ACh infusion. Results are expressed as mean (SD) and were analysed by an independent statistician using an ANOVA model. A two-sided p value <0.05 was considered significant. NCT02666235.

Results: 75 patients provided consent, and 60 (mean age 57.5 years, 80% male) were eligible and completed the protocol (n=30 RIC, n=30 sham) The LAD, LCx and RCA were evaluated in 13 (21.7%), 20 (33.3%), and 27 (45.0%) patients, respectively. The mean percentage change in coronary luminal diameter was -13.3% (22.3) and -2.0% (17.2) in the sham and RIC groups respectively, with a significant mean percentage difference (11.32%, 95% CI: 1.2 to 21.4, p=0.0317). There were no between-group changes in non-endothelial dependent vasodilation or the circulating markers of endothelial function.

Conclusion: RIC improves coronary artery endothelial function in patients with stable CAD. Potentially, enhanced coronary endothelial function may contribute to the cardioprotective effects of RIC in patients with CAD. This result is not associated with changes circulating molecules that reflect endothelial function.

Table 1
Sham (n=30)RIC (n=30)Between group difference in change from baseline
Mean (SD)Mean (SD)Mean (CI)
Mean coronary diameter (mm):
  1. Baseline2.402 (0.530)2.553 (0.543)
  2. Maximum ACh dose administered2.083 (0.719)2.498 (0.659)11.32% (1.24, 21.4), p=0.0317
  3. Following IC GTN2.588 (0.481)2.781 (0.515)1.18% (-3.38, 5.75), p=0.6133
Myeloperoxidase (MPO) (ng/ml)Pre 3.7 (5.1)Pre 3.8 (3.2)-0.5 ng/ml (-2.15, 1.15)
Post 3.4 (3.8)Post 2.9 (2.3)p=0.5520
Interleukin-6 (IL-6) (pg/ml)Pre 3.5 (2.7)Pre 3.4 (2.1)0.32 pg/ml (-0.71, 1.36)
Post 2.8 (1.4)Post 3.0 (1.9)p=0.5432
tissue Plasminogen Activator (tPA) (ng/ml)Pre 5.7 (1.7)Pre 6.0 (2.0)0.45 ng/ml (-0.24, 1.14)
Post 5.4 (2.2)Post 6.2 (2.6)p=0.2034
von Willebrand Factor (vWF) (U/ml)Pre 144.3 (24.8)Pre 137.7 (26.6)3.31 U/ml (-4.58, 11.19)
Post 138.3 (26.4)Post 135.0 (32.0)p=0.4147

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are